COVID-19 Clinical Trial Pipeline Advances With 180+ Companies and 200+ Therapies

The COVID-19 clinical trial pipeline continues to demonstrate substantial research activity, with more than 180 companies developing over 200 pipeline therapies across different stages of clinical and nonclinical development. DelveInsight’s “COVID-19 Pipeline Insight 2026” report provides a detailed assessment of emerging therapeutics, clinical strategies, drug mechanisms, development stages, routes of administration, and commercial opportunities within the COVID-19 treatment landscape.

(Albany, New York, USA) September 05, 2026- DelveInsight’s “COVID-19 Pipeline Insight 2026” report provides comprehensive insights about 180+ companies and 200+ pipeline drugs in the COVID-19 pipeline landscape. It covers the COVID-19 pipeline drug profiles, including clinical and nonclinical stage products. It also covers the COVID-19 therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Discover the latest drugs and treatment options in the COVID-19 Pipeline @ COVID-19 Pipeline Outlook - https://www.delveinsight.com/report-store/covid-19-pipeline-insight?utm_source=apac&utm_medium=promotion&utm_campaign=akpr 

Key Developments in the COVID-19 Clinical Trial Pipeline

• Recent clinical research demonstrates continued efforts to improve prevention and treatment strategies for different COVID-19 populations. On September 01, 2026, Wits Health Consortium (Pty) Ltd highlighted a study evaluating the effectiveness of a homologous boost of the Ad26.COV2.S COVID-19 vaccine following the prime dose among Sisonke participants in South Africa. The study aims to evaluate vaccine effectiveness among boosted, unboosted, vaccinated, and unvaccinated populations.
• On August 25, 2026, Pfizer conducted a Phase III study evaluating the efficacy and safety of ibuzatrelvir, both alone and in combination with intravenous remdesivir, compared with remdesivir alone. The study focuses on severely immunocompromised adults with symptomatic COVID-19 who are hospitalized or non-hospitalized at baseline with mild-to-moderate disease.
• DelveInsight’s COVID-19 Pipeline report depicts a robust space with 180+ active players working to develop 200+ pipeline therapies for COVID-19 treatment.
• The leading COVID-19 Companies such as Ansun Pharm, Biophytis, MetrioPharm, GeneOne Life Science, Shionogi, Sinocelltech, Laurent Pharmaceuticals, Frontier Biotechnologies, Eyegene, aptaTargets, Veru Inc., Corvus Pharmaceuticals, Revive Therapeutics, Regeneron Pharmaceuticals, Hoffmann-La Roche, CytoDyn, Incyte Corporation/Novartis, SAB Biotherapeutics, Moderna Therapeutics, Pfizer, FibroGen, Arch Biopartners, Senhwa Biosciences, Ionis Pharmaceuticals, GlycoMimetics, Akari Therapeutics, Serpin Pharma and others.
• Promising COVID-19 Pipeline Therapies such as Calcium Dobesilate, Mannitol, Interferon-Alpha2B, WPV01, ILT101, Ibuzatrelvir, Remdesivir, and others.

Get insights into COVID-19 clinical trials, emerging therapies, and leading companies with DelveInsight @ COVID-19 Treatment Drugs - https://www.delveinsight.com/sample-request/covid-19-pipeline-insight?utm_source=apac&utm_medium=promotion&utm_campaign=akpr 

COVID-19 Disease Overview and Ongoing Therapeutic Needs

COVID-19 is an infectious disease caused by SARS-CoV-2, a virus capable of evolving through genetic changes and mutations. Clinical manifestations can range from asymptomatic infection to severe respiratory disease. Common symptoms include fever, cough, fatigue, shortness of breath, sore throat, headache, and muscle aches. Loss of taste or smell has also been associated with COVID-19, while some patients may experience gastrointestinal symptoms.

Severe disease can progress to pneumonia, respiratory distress, and multi-organ complications. The continuing emergence of viral variants has supported the need for adaptable preventive and therapeutic approaches. Consequently, researchers continue to investigate antiviral agents, antibodies, vaccines, immune-based therapies, and other treatment strategies designed to address evolving clinical requirements.

Emerging COVID-19 Drugs and Pipeline Therapies

Several emerging candidates illustrate the diversity of approaches being explored across the COVID-19 pipeline.

VYD-2311, developed by Invivyd, Inc., is a monoclonal antibody candidate intended to provide prophylactic and therapeutic options for COVID-19. Its development incorporates molecular evolution designed to optimize neutralization against contemporary SARS-CoV-2 lineages. The candidate is currently being evaluated in Phase III development.